Details of the Drug

General Information of Drug (ID: DM92P0F)

Drug Name
Sisomicin
Synonyms
Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ
ATC Code
J01GB08: Sisomicin
J01GB: Other aminoglycosides
J01G: AMINOGLYCOSIDE ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 447.5
Logarithm of the Partition Coefficient (xlogp) -5.1
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 8
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 1 mL/min/kg [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.4 hours [1]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.70337 micromolar/kg/day [2]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [1]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.19 L/kg [1]
Chemical Identifiers
Formula
C19H37N5O7
IUPAC Name
(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
Canonical SMILES
CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CN)N)N)N)O
InChI
InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
InChIKey
URWAJWIAIPFPJE-YFMIWBNJSA-N
Cross-matching ID
PubChem CID
36119
ChEBI ID
CHEMBL9169
CAS Number
32385-11-8
UNII
X55XSL74YQ
DrugBank ID
DB12604
INTEDE ID
DR2408
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Aminoglycoside phosphotransferase (aph-Ib)
Main DME 		DE5WGIM A0A075C7U3_CAMJU Substrate [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
2 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
3 Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.